HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
about
Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosisPotential Use of Biological Proteins for Liver Failure TherapyClinical Advancements in the Targeted Therapies against Liver Fibrosis.Evolving therapies for liver fibrosis.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Future therapy of portal hypertension in liver cirrhosis - a guess.Pathobiology of liver fibrosis: a translational success storyRhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.Portal hypertension as immune mediate disease.Hepatic stellate cells: central modulators of hepatic carcinogenesis.Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver CirrhosisInterplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis.Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosisEffects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertensionExperimental liver fibrosis research: update on animal models, legal issues and translational aspects.New cellular and molecular targets for the treatment of portal hypertension.Dynamic expression of miR-126* and its effects on proliferation and contraction of hepatic stellate cells.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Novel treatment options for portal hypertension.Hepatic stellate cells as key target in liver fibrosis.Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosisPotential drug mechanism(s) targeting the contractile status of hepatic stellate cells.Acute liver injury induced by low dose dimethylnitrosamine alters mediators of hepatic vascular flow.Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosisTerutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.Rho-kinase inhibition is beneficial in fibrosis.Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.Research progress on signaling pathways in cirrhotic portal hypertension
P2860
Q26742049-7D7F3573-4B21-4499-840B-7FD6A4BDE4E4Q26781325-66C45450-4DDA-4F4A-BA81-163C6364E64BQ28078684-D71DD815-C8E5-4709-B98B-64595874EDABQ30539166-649F0D39-520D-4218-A00A-EF517300008DQ34386625-ADC4FC54-D2DC-408B-8BEC-A358ED08D82AQ34446521-2DE7567D-E5D2-40DA-8442-CFBBEA6FC853Q34462733-2FE477E4-4BCB-49F3-B90C-1890EFE291C3Q35008515-BF02DB09-95C5-4E75-BCFB-6BA6B310F858Q35136411-C18342D0-B2D2-47CA-AF9D-5FFE547B6027Q35197361-1F948D4A-5997-4C9E-AB01-7DF266A56C68Q35642468-5C36F8B0-F532-4DDC-A92E-921166A680C0Q35787734-23C2CD4D-3A32-4AF0-84C3-C4E212F46CC9Q36339714-0F963E7C-B996-45B9-9253-AB51DD47EE45Q36875004-79F026D3-00A6-4CA6-88FE-99814BF25D2AQ37204720-43961A80-60C6-4343-AFAA-651FBC81C893Q37363773-8E32FDB0-85A0-49B0-802D-DD37E1C68C21Q38383418-7EF8E048-8C83-4F92-B0E8-D1CB1100B192Q38484362-F345D78C-9E32-4D48-B932-546101BEE40AQ38540088-E1C3F96E-5392-4263-B26D-D8F8619055E0Q38680437-5854C90F-55D5-44E5-9C43-26A6622BE7D1Q40200602-AC0EF20A-EC3E-49E8-9D3F-3EF2049185FAQ41029212-DA7F0F9E-C51F-4050-881C-D80BA3B12178Q41107620-5FF80442-3FD1-4127-95BA-775F6EB6F438Q41569005-325567A4-196C-446C-BC3B-F2DF8BE910EDQ41681165-4B34C37F-2B60-4EF7-9375-459118C23F39Q41870298-4F7C8B3A-9B58-475C-9538-12678BBB6C73Q44582406-6E57D816-3699-497E-8BD1-3E486705F06DQ53784652-C945B5D9-13E3-40F9-8DA4-69E3A514A872Q53817185-A828B92E-30AF-4E14-8B38-7AC4B9A2B3C7Q55340936-65518885-CE02-447D-88C9-CE3363376004Q57069571-1F22F458-B229-4176-9875-98DB7D7B8F8A
P2860
HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@en
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@nl
type
label
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@en
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@nl
prefLabel
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@en
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@nl
P2093
P1476
HSC-specific inhibition of Rho ...... ithout major systemic effects.
@en
P2093
Iren Heidari
Klaas Poelstra
Leonie Beljaars
Marike Marjolijn Van Beuge
Michaela Granzow
Sabine Klein
Sebastian Huss
Sibel Kilic
Tilman Sauerbruch
P304
P356
10.1016/J.JHEP.2012.07.033
P577
2012-08-06T00:00:00Z